21
Participants
Start Date
October 30, 2023
Primary Completion Date
February 12, 2025
Study Completion Date
February 12, 2025
ALE.C04
Q3W
Pembrolizumab
200mg Q3W
Inselspital, University Hospital Bern, Bern
Candiolo cancer Center,FPO IRCCS, Candiolo
Istituto Europeo Di Oncologia S.R.L., Milan
Oncopole Claudius Regaud, Iuct-Oncopole, Toulouse
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre, Bordeaux
Gabrail Cancer Center Research, Canton
Karmanos Cancer Institute, Detroit
Washington University School of Medicine, Lake Saint Louis
Banner MD Anderson Cancer Center, Gilbert
University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles
National Cancer Centre Singapore, Singapore
Tan Tock Seng Hospital, Singapore
Yale University Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
University Health Network, Princess Margaret Cancer Centre, Toronto
Institut Gustave Roussy, Villejuif
Prince Of Wales Hospital, Hong Kong
Fondazione Irccs Istituto Nazionale Dei Tumori Di Milano, Milan
MD Anderson Cancer Center, Madrid
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Incliva Biomedical Research Institute - Hospital Clinico Universitario Valencia, Valencia
Vall d'Hebron Institute of Oncology, Barcelona
Lead Sponsor
Alentis Therapeutics AG
INDUSTRY